It is worth mentioning that, as occurs with other rheumatic diseases, the current tools used to predict the individual’s absolute risk for CV disease (such as lipid profile, CRP or other inflammatory markers) were found to underestimate the actual CV risk of patients with axSpA12. This evidence concerns the gene CRP and rheumatic disorder.